Adult Spinal Muscular Atrophy (SMA) China Registry
← catalyst calendarNCT05618379 · readout in 652 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200estimated
Sites
12
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-06 | actual | When the study began enrolling |
| Primary completion | 2028-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Atrophy, Spinal
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Characterized by Natural History of 5q-SMA Observed Among Adult Chinese Participants
measured Up to 60 Months
Number of Participants Characterized by Utilization of Disease Modifying Therapies (DMTs) of 5q-SMA Observed Among Adult Chinese Participants
measured Up to 60 Months
Publications
- PMID 41761140 — linked by the registry
- PMID 41461996 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed